SEC Form 4/A · accession 0001209191-17-021449
PLUS THERAPEUTICS, INC. · CNSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
John David Harris
Officer — VP and GM Cell Therapy
Period of report
Mar 8, 2017
Accepted (ET)
Mar 17, 2017 · 5:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001095981
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F1 | $1.55 | Mar 8, 2017 | A | 31,100 | A | — | Mar 8, 2027 | Common Stock | 31,100 | 31,100 | D |
Explanation of responses
- F1Option shares shall vest and become exercisable over four (4) years in forty-eight consecutive monthly installments.
Remarks
On March 10, 2017, the reporting person filed a Form 4 reporting the grant of an option that reflected an incorrect number of option shares. This amended Form 4 is being filed to correct the number of option shares previously reported.